Project Grant HT94252310885
Award Date
9/1/23
Completion Date
8/31/27
Dollars Obligated
$2M
Federal Agency
Defense Health Agency
Awardee
Deakin University (WES6DBHULKE3)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...
The University of Sydney, through its International Clinical Trials Symposium division, was awarded a $1,352,341 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, effective September 30, 2024, supports a study on the comparative effectiveness of exercise, cognitive behavioral therapy, and their combination for people with chronic musculoskeletal pain and poor sleep. The research aims to transform...
This $2,317,051 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on September 15, 2023. The grant funds a clinical trial to evaluate the use of vagus nerve stimulation (VNS) paired with prolonged exposure therapy to treat chronic post-traumatic stress disorder (PTSD). The University of Texas at Dallas (UTD) and Baylor Research Institute will serve as clinical sites for the study. UTD, led by Principal Investigator...
The Defense Health Agency has awarded a $1.632 million Project Grant to the Ocean State Research Institute, Inc., a non-profit research organization, to investigate the long-term outcomes of antipsychotic medication use in U.S. veterans with post-traumatic stress disorder (PTSD). This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. As...
This $170,712 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research on the comparative effectiveness of exercise, cognitive behavioral therapy, and their combination for people with chronic musculoskeletal pain and poor sleep. The research will be conducted by The University of Queensland (UQ) in Australia over a 4-year period from September 2024 to September 2028. UQ is a leading research university...
This $3,141,404.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports a randomized controlled trial at Rush University Medical Center to evaluate the efficacy of combined cognitive processing therapy and stellate ganglion blocks for treating post-traumatic stress disorder (PTSD). The award, which runs from September 1, 2024 to August 31, 2028, will fund this advanced medical research initiative...
This $2,997,922 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research at Florida State University (FSU) to develop rapid, non-invasive brain stimulation treatments for post-traumatic stress disorder (PTSD). The award, which runs from September 30, 2024 to September 29, 2028, will enable FSU's Sponsored Research Administration division to conduct cutting-edge scientific studies to advance...
The University of Melbourne received a $1,109,929 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop a neurotrophin therapy for clinical translation. The grant, awarded on September 1, 2024, will support research aimed at improving health outcomes for military service members, veterans, and the broader public by advancing innovative treatments for neurological disorders. The three-year project will...
This federal Project Grant award in the amount of $633,310.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, with a performance period from July 1, 2024 to June 30, 2027, will fund the University of Haifa in Israel to develop a novel drug to prevent PTSD or reduce symptoms in individuals already diagnosed with PTSD. The University of Haifa has a track record of conducting academic research projects across various...
This federal Project Grant award of $2,993,024.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a randomized controlled trial of lethal means safety counseling for service members and civilians with post-traumatic stress disorder (PTSD). The study, titled "FIREARM SAFETY IN PTSD (FASP): A RANDOMIZED CONTROLLED TRIAL OF LETHAL MEANS SAFETY COUNSELING AMONG SERVICE MEMBERS AND CIVILIANS WITH PTSD", will be conducted by...